We’re committed to meaningfully integrating sustainability considerations into our business practices and culture.
Clinical research and development is complex. Finding the right partner shouldn’t be.
The work we do has a global impact, and we are committed to making it a positive one. Our corporate sustainability practice enables us to engage meaningfully with stakeholders, empower our team members, reduce our environmental impact, and evolve our business model through innovation.
Sustainable goals for a sustainable future.
We support the United Nations’ 17 Sustainable Development Goals, and our corporate goals align with three in particular:
- Health and Well-Being
- Gender Equality
- Industry Innovation and Infrastructure
We are also an IMPACT 2030 partner. IMPACT 2030 is a private sector, partnership-led initiative to achieve the UN’s goals. By working together, we believe we can make our world a healthier, more prosperous, and peaceful place.
Read more about our partnership with IMPACT2030You may also be interested in:
White Paper
Alzheimer's Disease Research 2018
PRA conducted a survey at the 2018 Alzheimer's Association International Conference in Chicago. Across the board we found that the research community…
White Paper
Strategies for Accelerating Rare Disease Clinical Development
Rare disease trials differ from those in most other therapeutic areas because the indications are more complex and involve smaller patient…
Case Study
PRA Revs Up Multiple Myeloma Study
A large biotech company selected PRA to conduct 2 global Phase III open-label studies to measure the safety and efficacy of a multiple myeloma drug.…